Skip to main content
. Author manuscript; available in PMC: 2021 Oct 15.
Published in final edited form as: Arch Biochem Biophys. 2020 Aug 18;692:108546. doi: 10.1016/j.abb.2020.108546

Figure 7: EGCG enhances sensitivity of 5-FU and doxorubicin on ERK inhibition in colon and lung cancer cells.

Figure 7:

A: HCT15 cells were treated with 1xIC50 EGCG (E), 10 μM 5-FU (F), or both (F+E) for 24 h. Immunoblots for phosphorylated/total ERK, Bcl-xL, and XIAP in whole cell protein extracts from HCT15 cells are shown. Loading control: β-Actin. Bands were quantified and results are expressed as a percentage of control. * p<0.05, ** p<0.01 vs. control. B: A549 cells were treated with 1xIC50 EGCG (E), 0.25 μM doxorubicin (D), or both (D+E) for 24 h. Immunoblots for phosphorylated/total ERK, Bcl-xL, and XIAP in whole cell protein extracts from A549 cells are shown. Loading control: β-Actin. Bands were quantified and results are expressed as a percentage of control. * p<0.05, ** p<0.01 vs. control.